Cuorips

Cuorips AAQS

The The AAQS of Cuorips (4894.T) as of Oct 28, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

Cuorips has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Cuorips in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Cuorips AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2021
4.00 JPY
Jan 1, 2022
4.00 JPY
Jan 1, 2023
4.00 JPY
Jan 1, 2024
4.00 JPY
Jan 1, 2025
4.00 JPY
Jan 1, 2026
4.00 JPY
The Cuorips AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuorips Stock analysis

What does Cuorips do? Cuorips Inc generates revenue through regenerative medical products, primarily human iPS cell-derived cardiomyocyte sheets, and its CDMO business. The company develops these products in-house and through joint research with universities, research institutions, and major pharmaceutical companies. The CDMO services utilize CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept. Customers include major pharmaceutical companies and research institutions seeking regenerative medical solutions for the heart and other areas. The firm's regenerative medical products target heart conditions, developed through internal research and collaborations. The CDMO business provides contract development and manufacturing services using CLiC-1, serving pharmaceutical companies and research organizations. Revenue streams are derived from product sales and CDMO contracts, with the company focusing on heart-related applications and expanding into other medical areas through partnerships. Cuorips Inc's business model centers on leveraging its proprietary technology in iPS cell-derived cardiomyocyte sheets and CLiC-1 facility to serve pharmaceutical and research sectors. The company's products and services are designed for regenerative medicine applications, particularly for cardiac treatments, with sales and contracts driven by partnerships with major pharmaceutical companies and research institutions. Cuorips is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cuorips stock

The AAQS of Cuorips is 4 in 2026.

On Eulerpool you can find the complete historical development of The AAQS Cuorips since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Cuorips

All Key Metrics — Cuorips